In our previous post, we explained that ustekinumab biosimilar pricing discounts of up to 90% still resulted in net prices of $3,000 or more per month. On August 18th, Accord Biopharma announced that it has launched its Imuldosa brand of ustekinumab biosimilar at a 92% wholesale acquisition cost (WAC) discount relative to Stelara. This bests the previous lowest WAC discount for the reference product (for Biocon’s Yesintek) and nudges the price down to about $2,300 range per month for a 90-mg prefilled syringe. Accord BioPharma is launching its vial formulation of Imuldosa at a 33% discount to Stelara.
In its press release, Accord BioPharma US President Chrys Kokino stated, “We believe that cost shouldn’t be a barrier to accessing proven, life-changing therapies. The launch of Imuldosa represents our commitment to going beyond simply providing biosimilar alternatives to delivering comprehensive solutions that can make a meaningful difference in patients’ lives. With our third biosimilar now available, we’re demonstrating that Accord BioPharma is at the forefront of biosimilar transformation, backed by the 50-year heritage of our parent company, Intas Pharmaceuticals.”
Accord currently markets two other biosimilars in addition to Imuldosa: Udenyca (pegfilgrastim) and Hercessi (trastuzumab). In addition, it is awaiting an FDA decision on BAT2506, a biosimilar form of golimumab, in May 2026.
